Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009034 | 0.74 | CCR1 (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6124121 | 0.72 | — | — | |
| SCHEMBL18237976 | 0.72 | ELANE (0.36) | — | |
| SCHEMBL26237386 | 0.72 | HSP90AA1 (0.30) | — | |
| SCHEMBL6842158 | 0.71 | CHEK1 (0.41) | — | |
| SCHEMBL24422532 | 0.70 | TLR8 (0.36) | — | |
| SCHEMBL24174573 | 0.70 | NOS3 (0.35) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13586024 | 0.69 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15689524 | 0.69 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20674652 | 0.69 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-10874675-B2 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190282582-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-09-19 | — | — | US | disclosed |
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329303-B2 | Heterocyclic inhibitors of monocarboxylate transporter | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
| US-9994555-B2 | Chromenone inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994555-B2 | Chromenone inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-06-12 | — | — | US | disclosed |
| US-9944646-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180009792-A1 | CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2013-10-03 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PI4KA 183/4885PI4K2B 544/4885PI4K2A 609/4885 |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20180009792-A1 | CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A3, SLC16A1, SLC16A7 | PI4KA 1343/4885PI4K2B 1928/4885PI4K2A 2050/4885 |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20190282582-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | SLC16A1, SLC16A3, SLC16A7 | PI4KA 1910/4885PI4K2B 2612/4885PI4K2A 2560/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | SLC16A1, SLC16A3, SLC16A7 | PI4KA 1910/4885PI4K2B 2612/4885PI4K2A 2560/4885 |
| US-10874675-B2 | Pteridine dione monocarboxylate transporter inhibitors | SLC16A1, SLC16A3, SLC16A7 | PI4KA 1910/4885PI4K2B 2612/4885PI4K2A 2560/4885 |
| US-10329303-B2 | Heterocyclic inhibitors of monocarboxylate transporter | SLC16A1, SLC16A3, SLC16A7 | PI4KA 1338/4885PI4K2B 2164/4885PI4K2A 2283/4885 |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CB | PI4KA 10/4885PI4K2B 14/4885PI4K2A 20/4885 |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PI4KA 14/4885PI4K2B 32/4885PI4K2A 26/4885 |
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | SLC16A1, SLC16A3, SLC16A7 | PI4KA 1910/4885PI4K2B 2612/4885PI4K2A 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.